CATHAY PAC AIR(00293): Liu Tiexiang has been appointed as an executive director and elected as the vice chairman of the board of directors.
Cathay Pacific (00293) announced that the following changes to the composition of the board of directors will take effect on December 24, 2025: Mr. Ma Chung Yin (Mr. Ma) has resigned as the company's non-executive director and vice chairman of the board of directors, and Mr. Liu Tiexiang (Mr. Liu) has been appointed as the company's non-executive director and elected as vice chairman of the board of directors.
CATHAY PAC AIR (00293) announced that the following changes to the board of directors will take effect from December 24, 2025: Mr. Ma Chung-hin (Mr. Ma) has resigned as the company's non-executive director and vice chairman of the board of directors, and Mr. Lau Tit-ho (Mr. Lau) has been appointed as the company's non-executive director and elected as vice chairman of the board of directors.
The following changes to the board of directors will take effect from the conclusion of the company's annual general meeting of shareholders on May 13, 2026: Mr. Ho Yee-lai (Mr. Ho) will retire from the Swire Group and step down as the company's executive director and chairman of the board of directors. The current non-executive director of the company, Mr. Pak Tak-lai (Mr. Pak), will be promoted to executive director and elected as chairman of the board of directors. Additionally, Mr. Ma Tin-wai will be appointed as the company's non-executive director.
Related Articles

Maiwei Biological (688062.SH): The clinical trial application for 9MW1911 injection has been approved by the FDA.

On December 23rd, BEISEN HOLDING (09669) spent 1.3298 million Hong Kong dollars to repurchase 182,000 shares.

Goldwind Science & Technology's shareholder Harmony Health has reduced its holding in the company by approximately 31.89 million shares.
Maiwei Biological (688062.SH): The clinical trial application for 9MW1911 injection has been approved by the FDA.

On December 23rd, BEISEN HOLDING (09669) spent 1.3298 million Hong Kong dollars to repurchase 182,000 shares.

Goldwind Science & Technology's shareholder Harmony Health has reduced its holding in the company by approximately 31.89 million shares.

RECOMMEND





